ArticleAAPS PharmSciTech2026
Design of Eudragit E100 Films Incorporating Lipoic Acid as a Permeability-Enhancing Platform for Prednisolone Delivery in the Treatment of Ophthalmic Diseases.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prednisolone (PRED), a widely used corticosteroid for the treatment of ocular inflammation, has limited bioavailability due to its poor water solubility. In this study, Eudragit E100-based films incorporating polyethylene glycol 400 (PEG) and α-lipoic acid (ALA) as plasticizers were developed and characterized to improve the ocular delivery and corneal permeability of PRED. ALA, which is also known for its antioxidant and therapeutic properties in ocular surface disorders, plays a dual role by enhancing both the mechanical properties and drug delivery performance of the films. The E100:PEG:ALA:PRED (1:0.3:0.2:0.2) formulation exhibited flexibility, mucoadhesion, and controlled-release behavior. Furthermore, cell viability and wound-healing assays were performed to evaluate the biocompatibility of the films. In addition, ex vivo permeability studies using porcine corneas revealed significantly enhanced PRED penetration compared with a commercial eye drop formulation (Sophipren Ofteno® 1%) and demonstrated that the films induced minimal corneal irritation. Based on these findings, Eudragit E100 films containing ALA, PEG, and PRED may represent a promising alternative to conventional ophthalmic suspensions, as they provide sustained drug release while potentially simplifying dosing regimens.
Indexed as
Identifiers
42728513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.